She Loves Me, She Loves Me Not: Do Biologics Decrease Glucocorticoid Morbidity in Adults with Severe T-Helper Cell Type 2 Asthma?

她爱我,她不爱我:生物制剂能否降低重度 T 辅助细胞 2 型哮喘成人患者的糖皮质激素发病率?

阅读:1

Abstract

Management of persistent air‐leaks (PAL) in mechanically ventilated patients is challenging as most patients are refractory to standard treatments. Herein, we report the successful management of persistent air‐leaks in a case series of seven patients. Patients were mechanically ventilated and presented severe air‐leaks that persisted 17.5 ± 6.2 days after chest drainage insertion. Patients were deemed unfit for surgical resection while talc pleurodesis was unfeasible in five patients or performed without success in two. Valves treatment was performed at bedside in the Intensive Care Unit. Chest drainage was removed 5.5 ± 3.1 days after valve insertion, and all patients were weaned off the ventilator 8.8 ± 3.4 days later. All but one patient was discharged 26.8 ± 10.2 days following the procedure. One patient died at 35 days due to systemic sepsis not related to valves. Valves were readily removed in four patients at a mean of 149 ± 12.7 days after the implant. Our study confirmed the safe and effective use of EBV treatment for the management of PAL refractory to standard treatment in mechanically ventilated patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。